Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) which is characterized by specific clinical and biological features. Typical APL cases are caused by PML::RARA fusion gene and are exquisitely sensitive to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Rarely, APLs are caused by atypical fusions involving RARA or, in fewer cases still, fusions involving other members of the retinoic acid receptors (RARB or RARG). To date, seven partner genes of RARG have been reported in a total of 18 cases of variant APL. Patients with RARG fusions showed distinct clinical resistance to ATRA and had poor outcomes. Here, we report PRPF19 gene as a novel partner of RARG and identify a rare interposition-type gene fusion in a variant APL patient with a rapidly fatal clinical course. The incomplete ligand-binding domain of RARG in the fusion protein may account for the clinical ATRA resistance in this patient. These results broaden the spectrum of variant APL associated molecular aberrations. Accurately and timely identification of these rare gene fusions in variant APL is essential to guide therapeutic decisions.

PPy coated nanoflower like CuCo2O4based onin situgrowth of nanoporous copper for high-performance supercapacitor electrodes.

General CuCo2O4electrodes suffer a very low reversible capacity and poor cycling stability because of easily fading phenomena and volume change during cycling. To optimize the electrode, a facile method is conducted to fabricate a novel electrode of Cu@CuCo2O4@polypyrrole nanoflowers. Due to larger specific surface area and more electrochemical reactive areas of CuCo2O4@polypyrrole nanoflowers, the pseudocapacitance of thein situgrown CuCo2O4@polypyrrole (912 F g-1at 2 A g-1) is much higher than the pristine CuCo2O4(618 F g-1at 2 A g-1). Remarkably, the CuCo2O4@polypyrrole (cathode) and active carbon (anode) are used to assemble an asymmetric supercapacitor, which exhibits a relatively high energy density of 90 Wh kg-1at a power density of 2519 W kg-1and 35 Wh kg-1at a high-power density of 9109 W kg-1, and excellent cycling stability (about 90.4% capacitance retention over 10 000 cycles). The prominent performance of CuCo2O4@polypyrrole makes it as a potential electrode for supercapacitor.

Two-dimensional SnO2 anchored biomass-derived carbon nanosheet anode for high-performance Li-ion capacitors.

Lithium-ion capacitors (LICs) combine the advantages of both batteries and supercapacitors; they have attracted intensive attention among energy conversion and storage fields, and one of the key points of their research is the exploration of suitable battery-type electrode materials. Herein, a simple and low-cost strategy is proposed, in which SnO2 particles are anchored on the conductive porous carbon nano-sheets (PCN) derived from coffee grounds. This method can inhibit the grain coarsening of Sn and the volume change of SnO2 effectively, thus improving the electrochemical reversibility of the materials. In the lithium half cell (0-3.0 V vs. Li/Li+), the as-prepared SnO2/PCN electrode yields a reversible capacity of 799 mA h g-1 at 0.1 A g-1 and decent long-term cyclability of 313 mA h g-1 at 1 A g-1 after 500 cycles. The excellent Li+ storage performance of SnO2/PCN is beneficial from the hierarchical structure as well as the robust carbonaceous buffer layer. Besides, a LIC hybrid device with the as-prepared SnO2/PCN anode exhibits outstanding energy and power density of 138 W h kg-1 and 53 kW kg-1 at a voltage window of 1.0-4.0 V. These promising results open up a new way to develop advanced anode materials with high rate and long life.

Clinical characteristics and laboratory analyses of acute myeloid leukemia with t(16;21)(p11;q22).

The present study reviewed three patients with acute myeloid leukemia (AML) who had the specific genetic abnormality t(16;21)(p11;q22). To investigate the clinical and laboratory characteristics of AML with t(16;21)(p11;q22) translocation, the similarities and differences of clinical characteristics and laboratory examinations were compared, and a literature review was conducted. According to the French-American-British classification system, patient 1 was M4, patient 2 was M1 and patient 3 was M2. The cytogenetic aberrations were 46, XY, t(16;21)(p11;q22)/47, idem, +21 for patient 1 and 46, XX, t(16;21)(p11;q22) for patients 2 and 3. Cytophagocytosis and cluster of differentiation 56 antigen expression were found in all three cases. The prognosis was poor in all the cases. AML with t(16;21)(p11;q22) is a specific subtype of AML that exhibits unique characteristics of morphology, immunology, cytogenetics and clinical features, as well as a poor prognosis. Stem cell transplantation may be the first and only choice for treatment.